Contravir Pharmaceuticals, Inc.

Ciclofilin Pharmaceuticals Corp.

Hepion Pharmaceuticals, Inc.

Daren R Ure

Mark D Abel

Alexander Hegmans

Bruce W Fenske

Dan J Trepanier

Shin Sugiyama

Robert T Foster

Patrick R Mayo

Daniel J Trepanier

Disclosed herein include methods, compositions, and kits suitable for use in preventing, treating or reverse fibrosis. The methods comprise administering to a subject in need thereof a composition comprising a cyclosporine analogue (for example, CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof. The compositions and kits comprise a cyclosporine analogue (for example, CRV431), or a pharmaceutically acceptable salt, solvate, stereoisomer thereof.

Use of cyclosporine analogues for treating fibrosis

Analogs of cyclosporin-A are disclosed comprising modifications of the substituents as the positions of amino acids 1 and 3, according to the following Formula. The disclosed compounds include compounds having affinity for cyclophilin, including cyclophilin-A, and reduced immunosuppressivity in comparison with cyclosporin-A and analogs thereof modified solely at position 1. 

Cyclosporine analogue molecules modified at amino acid 1 and 3

Growing community of inventors

Edmonton, Canada

Daren R Ure